Applied DNA Sciences Inc
NASDAQ:APDN
Net Margin
Applied DNA Sciences Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Applied DNA Sciences Inc
NASDAQ:APDN
|
2m USD |
-1 218%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
995.2B USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
185.3B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
150.6B USD |
14%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
38.8B CHF |
10%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
278.5B CNY |
32%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
33.8B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
32.8B USD |
8%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
27.5B USD |
21%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
17.2B EUR |
8%
|
Applied DNA Sciences Inc
Glance View
Applied DNA Sciences, Inc. engages in the developing and marketing DNA-based technology solutions utilizing LinearDNA, large-scale polymerase chain reaction (PCR) based manufacturing platform. The company is headquartered in Stony Brook, New York and currently employs 78 full-time employees. The company went IPO on 2001-08-24. The firm is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Company’s proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. Applied DNA also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Company’s Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Applied DNA Sciences Inc's most recent financial statements, the company has Net Margin of -1 218.5%.
You don't have any saved screeners yet